Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NL005 in Acute Myocardial Infarction (Phase II)
CTR20201682Phase 2Completed
- Sponsor
- Northland Biotech
- Start
- Aug 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of gletimbetasin in acute ST-segment elevation myocardial infarction (STEMI), sponsored by Northland Biotech. Started Aug 2020; status: completed.
02
Drugs
gletimbetasin
03
Conditions
acute ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on CTR20201682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201682.